|
시장보고서
상품코드
2032485
자가 줄기세포 및 비줄기세포 기반 치료법 시장 보고서 : 유형, 용도, 최종 사용자, 지역별(2026-2034년)Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report by Type, Application, End User, and Region 2026-2034 |
||||||
세계의 자가 줄기세포 및 비줄기세포 기반 치료법 시장 규모는 2025년에 95억 달러에 이르렀습니다. 향후 IMARC Group은 2034년까지 시장 규모가 243억 달러에 이르고, 2026-2034년 CAGR 10.63%를 나타낼 것으로 예측했습니다. 생명을 위협하는 질병의 유병률 증가, 고령 인구 증가, 줄기세포 기술의 지속적인 발전은 시장을 이끄는 주요 요인 중 일부입니다.
자가 줄기세포 치료는 환자 자신의 줄기세포를 이용하여 손상된 조직이나 장기를 복구하거나 각종 질환을 치료하는 의료 시술입니다. 이 시술은 보통 골수나 지방조직 등에서 환자의 체내에 존재하는 줄기세포를 채취하여 처리한 후 체내에 재주입하는 시술입니다. 반면, 비줄기세포 기반 치료법은 면역세포, 섬유아세포, 근육세포 등 줄기세포가 아닌 세포를 이용해 손상된 조직이나 장기를 복구하거나 재생시키는 치료법입니다. 자가 줄기세포 치료는 심혈관 질환, 신경퇴행성 질환, 자가면역질환 치료에 사용되며, 비줄기세포 기반 치료법은 만성 상처, 심장병, 파킨슨병 치료에 사용됩니다.
자가 줄기세포 및 비줄기세포 기반 치료제 시장 동향 :
세계 자가 줄기세포 및 비줄기세포 기반 치료제 시장의 성장은 주로 흡연, 부적절한 식습관, 소비자의 좌식 생활로 인한 암, 당뇨병, 심혈관 질환, 신경 퇴행성 질환의 유병률 증가에 의해 주도되고 있습니다. 여기에 고령 인구 증가와 자가 줄기세포 및 비줄기세포 기반 치료법에 대한 수요 증가가 더해져 시장 전망을 밝게 하고 있습니다. 또한, 재생 의료를 위한 혁신적인 자가 줄기세포 치료제의 지속적인 개발과 맞춤형 의료에 대한 수요가 확산되고 있는 것은 시장에 수익성 높은 성장 기회를 가져다 줄 것입니다. 이와 더불어 저침습적 치료의 인기 급상승, 줄기세포 치료에 대한 수용성 확대, 줄기세포 연구에 대한 정부의 재정적, 규제적 지원 등 정부의 우호적인 정책 시행이 시장 확대에 힘을 실어주고 있습니다. 또한 줄기세포 기술의 지속적인 발전으로 연구자들은 줄기세포의 분화를 더 잘 제어하고 개선된 효과적인 치료법을 개발할 수 있게 되었으며, 이는 중요한 성장 촉진요인으로 작용하고 있습니다. 이 외에도 헬스케어 부문의 강력한 성장, 광범위한 조사 개발(R&:D) 활동, 소비자의 건강 인식 증가, 그리고 유리한 상환 정책 등이 시장 성장에 기여하고 있습니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문
- 지금까지 세계 자가 줄기세포 및 비줄기세포 기반 치료제 시장은 어떻게 성장해 왔으며, 향후 몇 년 동안 어떤 추세를 보일 것인가?
- 세계 자가 줄기세포 및 비줄기세포 기반 치료제 시장 성장 촉진요인, 억제요인 및 기회는 무엇인가?
- 각 촉진요인, 제약 요인 및 기회는 세계 자가 줄기세포 및 비줄기세포 기반 치료제 시장에 어떤 영향을 미치고 있는가?
- 주요 지역 시장은?
- 자가 줄기세포 및 비줄기세포 기반 치료제 시장에서 가장 매력적인 시장은 어느 국가인가?
- 시장 유형별 시장 분석은?
- 자가 줄기세포 및 비줄기세포 기반 치료제 시장에서 가장 매력적인 유형은?
- 용도별 시장 현황은?
- 자가 줄기세포 및 비줄기세포 기반 치료제 시장에서 가장 매력적인 용도는?
- 최종 사용자별 시장 현황은?
- 자가 줄기세포 및 비줄기세포 기반 치료제 시장에서 가장 매력적인 최종 사용자는?
- 세계 자가 줄기세포 및 비줄기세포 기반 치료제 시장 경쟁 구도는 어떻게 형성되어 있는가?
- 세계 자가 줄기세포 및 비줄기세포 기반 치료제 시장의 주요 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 자가 줄기세포 및 비줄기세포 기반 치료법 시장
제6장 시장 분석 : 유형별
제7장 시장 분석 : 용도별
제8장 시장 분석 : 최종 사용자별
제9장 시장 분석 : 지역별
제10장 촉진, 억제 및 기회
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
JHS 26.05.18The global autologous stem cell and non-stem cell based therapies market size reached USD 9.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 24.3 Billion by 2034, exhibiting a growth rate (CAGR) of 10.63% during 2026-2034. The increasing prevalence of life-threatening diseases, the expanding geriatric population, and ongoing advancements in stem cell technologies represent some of the key factors driving the market.
Autologous stem cell therapy is a medical procedure in which a patient's stem cells are used to repair damaged tissues and organs or treat various diseases. The procedure involves harvesting stem cells from a patient's body, usually from bone marrow or adipose tissue, and then processing and injecting them back into the body. Non-stem cell-based therapies, on the other hand, involve using cells that are not stem cells, such as immune cells, fibroblasts, and muscle cells, to repair or regenerate damaged tissues or organs. Autologous stem cell therapy is used to treat cardiovascular diseases, neurodegenerative diseases, and autoimmune disorders, while non-stem cell-based therapies are employed in treating chronic wounds, heart disease, and Parkinson's disease.
AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET TRENDS:
The growth of the global autologous stem cell and non-stem cell based therapies market is primarily driven by the increasing prevalence of cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases due to smoking, poor diet, and sedentary lifestyles of consumers. Besides this, the rising geriatric population and the growing demand for autologous stem and non-stem cell based therapies are creating a positive outlook for the market. Moreover, the ongoing development of innovative autologous stem cell therapies for regenerative medicine and the widespread demand for personalized therapies are presenting remunerative growth opportunities for the market. In addition to this, the surging popularity of minimally invasive treatments, the expanding acceptance of stem cell therapies, and the implementation of favorable government initiatives, such as financial and regulatory support for stem cell research, are aiding in market expansion. Furthermore, continuous advancements in stem cell technologies have enabled researchers to better control the differentiation of stem cells and develop improved and effective treatments, which, in turn, is acting as a significant growth-inducing factor. Besides this, the bolstering growth of the healthcare sector, extensive research and development (R&D) activities, the escalating health consciousness among consumers, and favorable reimbursement policies are contributing to the market growth.
KEY MARKET SEGMENTATION:
Type Insights:
- Autologous Stem Cells
- Autologous Non-Stem Cells
Application Insights:
- Cancer
- Neurodegenerative Disorders
- Cardiovascular Disease
- Orthopedic Diseases
- Others
End User Insights:
- Hospitals
- Ambulatory Surgical Centers
- Research Facilities
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for autologous stem cell and non-stem cell based therapies. Some of the factors driving the North America autologous stem cell and non-stem cell based therapies market included the expanding prevalence of chronic diseases, the rising demand for personalized medicines, and continuous advancements in stem cell technologies.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global autologous stem cell and non-stem cell based therapies market. Detailed profiles of all major companies have also been provided. Some of the companies covered include BrainStorm Cell Limited, Cytori Therapeutics Inc., Holostem Terapie Avanzate S.r.l., Lisata Therapeutics, U.S. Stem Cell Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global autologous stem cell and non-stem cell based therapies market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global autologous stem cell and non-stem cell based therapies market?
- What is the impact of each driver, restraint, and opportunity on the global autologous stem cell and non-stem cell based therapies market?
- What are the key regional markets?
- Which countries represent the most attractive autologous stem cell and non-stem cell based therapies market?
- What is the breakup of the market based on the type?
- Which is the most attractive type in the autologous stem cell and non-stem cell based therapies market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the autologous stem cell and non-stem cell based therapies market?
- What is the breakup of the market based on the end user?
- Which is the most attractive end user in the autologous stem cell and non-stem cell based therapies market?
- What is the competitive structure of the global autologous stem cell and non-stem cell based therapies market?
- Who are the key players/companies in the global autologous stem cell and non-stem cell based therapies market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Autologous Stem Cells
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Autologous Non-Stem Cells
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Application
- 7.1 Cancer
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Neurodegenerative Disorders
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Cardiovascular Disease
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Orthopedic Diseases
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Ambulatory Surgical Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Research Facilities
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 BrainStorm Cell Limited
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Cytori Therapeutics Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Holostem Terapie Avanzate S.r.l.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Lisata Therapeutics
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 U.S. Stem Cell Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.1 BrainStorm Cell Limited
